Chronic kidney disease increases the risk of cardiovascular events associated with type 2 diabetes. A clinical trial sought to discover if finerenone would help patients with both of these conditions.
Half of the study participants were randomly prescribed oral vitamin D3 and continued their prescribed metformin for 6 months; the remainder received metformin only.
Researchers sought to identify which medications for type 2 diabetes may be associated with severity of COVID-19.
The association between GLP-1 RA therapy and cardiovascular outcomes in type 2 diabetes was assessed.
Using certain glucose inhibitors in people with type 2 diabetes may also have a beneficial effect on renal and cardiovascular health, and weight.
Researchers studied the effect of dietary L-arginine on the incidence of type 2 diabetes.
Researchers assessed how gut microbiota changes are associated with anthropometric, metabolic, and inflammatory profiles following metabolic surgery in adults with type 2 diabetes and mild obesity.
Investigators sought to assess the impact of treatment with SGLT2 inhibitors on risk of all-cause mortality, cardiovascular disease, or hospitalization for heart failure or chronic kidney disease in patients with type 2 diabetes.
Increase in rate of days alive and out of hospital mainly due to drop in rate of days dead for patients with T2DM, worsening heart failure.
SGLT2i use was linked to reduced mortality and morbidity in a real-world cohort of patients with heart failure and diabetes.
